Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented data at the 2026 American Society of Clinical Psychopharmacology Annual Meeting revealing that opioid use remains prevalent among U.S. adults diagnosed with fibromyalgia, despite longstanding treatment guidelines discouraging their use. The findings, based on a retrospective analysis of over 261,000 patients in the Symphony Health claims database, show that approximately 40% of commercially insured, Medicare Advantage, and Medicaid patients with fibromyalgia were prescribed at least one opioid, with tramadol and oxycodone being the most common prescriptions.
This data underscores a significant gap between clinical practice and evidence-based recommendations, according to Tonix. The company emphasized the need for greater awareness of FDA-approved, non-opioid treatment options, including its recently approved fibromyalgia therapy, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg). TONMYA is the first new treatment for fibromyalgia in more than 15 years and represents a potential shift in managing the condition without the risks associated with opioids.
The implications of this announcement are substantial. For patients, the continued high use of opioids despite guidelines suggests many are not receiving optimal care, potentially exposing them to risks of dependence, overdose, and other adverse effects. For the healthcare industry, the data highlights a persistent challenge in translating clinical guidelines into practice, which may prompt further educational efforts or policy interventions. For Tonix, the findings support the market need for TONMYA and other non-opioid therapies, potentially driving adoption and influencing prescribing patterns.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, the company’s CNS commercial infrastructure supports its marketed acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also exploring TONMYA’s potential in Phase 2 trials for major depressive disorder and acute stress disorder. The company’s pipeline includes TNX-2900, Phase 2 ready for Prader-Willi syndrome, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection.
For investors, the real-world data may strengthen the case for TONMYA’s commercial success and broader pipeline value. The announcement comes as the opioid crisis continues to be a public health priority, making non-opioid alternatives increasingly attractive. Tonix’s data presentation aligns with efforts to bridge the gap between evidence and practice, potentially improving outcomes for fibromyalgia patients and reducing reliance on opioids.
More information about Tonix and its pipeline can be found in the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/6AtjR.
